Genzyme maintained by Merrill at neutral

Genzyme Corp. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating after the company announced that the FDA extended the Biological License Application for Myozyme to treat the rare muscular disorder Pompe disease by 90 days to April 28 from Jan. 28 to review additional information. Despite the delay, Merrill said sales estimates of $65 million in 2006 and $170 million in 2007 will not be changed. Shares of the Cambridge, Mass., biotechnology company were up 40 cents, or 0.55%, at $73.22 on volume of 1,618,964 shares versus the three-month running average of 2,158,610 shares. (Nasdaq: GENZ)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.